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Breast cancer is the most prevalent form of
cancer in North American women (1,2).
The death rate from breast cancer is decreas-
ing while the incidence is slightly increasing,
but this increase is statistically significant
only in black American women (2). The
acknowledged risk factors for breast cancer
are genetic predispositions (3–6) and repro-
ductive factors (7,8). These risk factors
account for only 30–50% of the cases
(5,9–12); thus, environmental factors (expo-
sure to manmade and natural chemicals,
dietary habits, lifestyle) are hypothesized to
account for the remaining cases.
The possibility that exposure to environ-
mental contaminants, such as organochlo-
rines, may be linked with breast cancer risk
was raised by some (9,13), although others
disagree (14–16). Organochlorines include a
large number of agricultural and industrial
chemicals and by-products of combustion
and incineration. Polychlorinated biphenyls
(PCBs), dioxins, and p,p´-dichlorodiphenyl-
trichloroethane (DDT) are lipophilic organo-
chlorines, they accumulate in fat, and they
are present at the µg to mg/kg levels in
human tissues and milk (17–27), conﬁrming
direct exposure of the mammary tissues.
Some epidemiologic investigations have
found no association, or even a negative one,
between human tissue levels of PCB
congeners, DDT, and p,p´-dichlorodiphenyl-
dichloroethene (DDE) and breast cancer
(28–38); but in specific subpopulations
(7,22,29,33,34,39–42) or by testing speciﬁc
congeners (27,33,43,44), some did detect
signiﬁcant associations. The hypothesis of a
link between organochlorine exposure and
breast cancer is challenged by the study of
accidentally exposed populations. People
accidentally exposed to mixtures containing
PCBs, polychlorinated dibenzo-dioxins and
-furans in central Taiwan in 1979 and in
western Japan in 1968 (45,46), and to
dioxin in 1976 in Seveso, Italy (47), have
not yet been reported to have an increased
rate of breast cancer.
Organochlorine compounds have
numerous effects in vivo and in vitro, which
suggest that they could modulate the devel-
opment of mammary tumors. These include
antiestrogenic (16) or estrogenic effects
(13,48,49) and alteration of thyroid (50–52)
and immune functions (53). In vitro, these
chemicals can decrease (54,55) or increase
(13,56) the proliferation of breast cancer
cells or immortalized breast epithelial cells,
by acting directly on the estrogen receptor or
indirectly via metabolic or crosstalk path-
ways (57,58), or by modulating apoptotic
processes (59,60). Deregulation of apoptosis
and interference with hormonal actions are
key factors influencing mammary tumor
development. Animal studies, because of dif-
ferent exposure protocols, demonstrate
inconsistencies in linking organochlorine
exposure with mammary tumor develop-
ment. Long-term standard regulatory studies
do not support an association between
dietary exposure to DDE, DDT, PCBs, or
2,3,7,8-tetrachlorodibenzo-p-dioxin
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Articles
The role of organochlorine (OC) exposure in the etiology of breast cancer remains controversial.
Thus, our objective was to determine whether the most abundant and toxic OCs found in human
milk could, when ingested during the neonatal period, modulate the development of mammary
tumors in the rat. We prepared a mixture composed of p,p´-dichlorodiphenyltrichloroethane
(DDT), its major metabolite, p,p´-dichlorodiphenyldichloroethene (DDE), and 19 polychlori-
nated biphenyls (PCB) based on their concentrations found in the milk of Canadian women.
Neonate rats at 1, 5, 10, 15, and 20 days of age were gavaged with this mixture, at 10, 100, and
1,000 times the amount that a human baby would consume. An additional group received 2.5 µg
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)/kg body weight (bw) by gavage at 18 days of age,
instead of the mixture. On day 21, all treatment groups, except for a control group and a 1,000-
mix group, received a single intraperitoneal injection of methylnitrosourea (MNU, 30 mg/kg bw),
the initiator of the carcinogenic process. The average number of rats per treatment group was 33.
Rats were sacriﬁced when their tumors reached 1 cm in size, or at 308 days of age. We prepared
mammary tumors and mammary gland whole mounts for histologic analysis. There were no sig-
nificant effects when only the malignant or only the benign tumors were considered. After all
benign and malignant lesions were pooled, the number of mammary tumors differed among all
MNU-treated groups (p = 0.02) with more lesions developing in the MNU-1,000× (median =
4.5; p = 0.05) and MNU-TCDD (median = 5.5; p = 0.07) compared to the MNU-0 rats (median
= 2). Compared to the MNU-0 group, the percentage of rats that developed palpable tumors
(benign plus malignant) was slightly higher (p = 0.06) in the MNU-TCDD group, but not in the
MNU-1,000× group. The percentage of palpable tumors that were malignant was higher (p =
0.02) in the MNU-100× group (15/16, 94%) than in the MNU-0 group (10/18, 56%). The
highest dose of the mixture delayed (p = 0.03) the development of tumors, but this was not
observed with the MNU-TCDD treatment. These results suggest that neonatal exposure to high
doses of organochlorines could favor the development of MNU-induced mammary lesions, but
also delays the development of palpable tumors in the rat. Key words: DDE, DDT, mammary
tumor, methylnitrosourea, organochlorines, PCB, rat, TCDD. Environ Health Perspect
109:739–747 (2001). [Online  13 July 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p739-747desaulniers/abstract.html(TCDD) with endocrine-related cancers in
adult animals; however, these studies have
limitations (61). DDT can either support
the growth of an estrogen-responsive tumor
in ovariectomized rats (62) or prevent mam-
mary tumor development in dimethylben-
zanthracene (DMBA)-treated rats (63).
3,3´,4,4´-tetrachlorobiphenyl (PCB #77)
can either potentiate the carcinogenic effect
of DMBA (64) or prevent further develop-
ment of mammary tumors in the rat (65).
Acute exposure to TCDD (66) or other aryl-
hydrocarbon receptor (Ah-R) agonists (67)
in postpubertal rats inhibited mammary
tumor development; however, development
of the tumors was promoted when TCDD
was administered in utero (68).
Overall, little attention has been devoted
to the effects of perinatal exposure to
organochlorines. Excretion of accumulated
contaminants through breast milk is a major
source of exposure to organochlorines for
nursing infants (69). The neonates and fetuses
in utero are exposed and, in animal studies,
accumulate tissue levels higher than those
measured in the mothers (70,71). Some have
hypothesized that changes in the endocrine
environment during the fetal and neonatal
periods could increase the probability of
future occurrence of breast cancer (22,72–76).
We observed that a high dose of a mixture of
the most abundant human milk contami-
nants (19 PCB congeners, p,p-DDT, and
p,p-DDE) stimulated the proliferation of
breast cancer cells in vitro (56). Thus, our
objective was to determine whether exposure
to this mixture by gavage from neonatal day
1 to day 20, or whether a single exposure to
TCDD at neonatal day 18 could modulate
the development of methylnitrosourea
(MNU)-induced mammary tumors.
Our results suggest that neonatal expo-
sure to this organochlorine mixture (19 PCB
congeners, p,p-DDT, and p,p-DDE) or to a
single dose of TCDD (2.5 µg/kg) before
MNU treatment favors the development of
mammary lesions, but the mixture at a high
dose delays the development of palpable
tumors in the rat.
Materials and Methods
Animal model. MNU is a DNA-methylating
agent believed to induce mammary tumor
development by creating O6-methylguanine
in the DNA, which activates the proto-onco-
gene Ha-ras by a G→A transition (second
nucleotide) of codon 12 (77–79). It has also
been suggested that MNU treatment selects
for pre-existing cells with Ha-ras oncomuta-
tions (80–82). We selected the MNU-treated
rat model because, a) as in the human dis-
ease, MNU-tumors are mostly estrogen
dependent; b) the carcinomas induced are
aggressive and locally invasive; c) in contrast
to DMBA, MNU has a short half-life (< 30
min) and need not be metabolized to
become active, allowing us to decrease the
confounding effects of metabolic enzyme
induction by the mixture and by DMBA
itself; and d) MNU treatment permitted us
to study the development of both malignant
and benign tumors within a shorter time
frame than studies that examined the devel-
opment of spontaneous mammary tumors,
which are mostly benign and take more than
27 weeks to develop (83). Finally, the MNU
was injected in prepubertal female rats at 21
days of age, a protocol shown to induce
tumors more rapidly than when MNU is
injected at 50 days of age (84). 
Mixture composition. DDT, DDE, and
PCB congeners detected in more than 75%
of breast milk samples from Canadian
women were included in the mixture accord-
ing to the median concentrations in milk fat
(20,21). Non–ortho-chlorinated PCBs (#77,
126, and 169) were also added to the mix,
according to the mean (median values were
not available) concentrations in human milk
fat (19). The doses were prepared to mimic
multiples (10×, 100×, and 1,000×) of the
typical daily intake of PCBs, DDT, and
DDE for a Canadian Caucasian newborn
drinking 120 mL breast milk/kg body
weight (bw) per day (19). Using the human
milk fat concentration of each organochlo-
rine and the milk fat consumption of a new-
born [3.7% milk fat (85)], we calculated the
daily intake of each organochlorine. All the
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Table 1. Concentrations of PCB congeners, DDT, and DDE in the 1,000× dosing mixture.
Human 1,000× 1,000× 1,000×
Family of Selected milk fatb Target concentrationc Analyzed concentrationd Amount gavaged per dosee
xenobiotics congenersa (ng/g) (µg/mL) (µg/mL) (µg/kg bw)
PCBsf
Non-ortho 77 0.008 0.03g 0.24 1.22
126 0.080 0.34 0.32 1.68
169 0.033 0.14 0.15 0.75
Mono-ortho 28 8 34.28 33.60 174.05
66 4 17.14 17.70 91.69
74 15 64.27 74.30 384.87
118 16 68.55 70.40 364.67
156 5 21.42 24.60 127.43
Di-ortho 99 23 98.54 122.00 631.96
128 4 17.14 16.10 83.40
138 27 115.68 124.00 642.32
153 27 115.68 141.00 730.38
170 9 38.56 37.60 194.77
180 18 77.12 81.80 423.72
183 3 12.85 19.00 98.42
187 7 29.99 34.40 178.19
194 3 12.85 16.60 85.99
201 4 17.14 16.10 83.40
203 3 12.85 13.60 70.45
DDT p,p´-DDE 233 1,000 1063.00 5506.34
p,p´-DDT 35 149.1 158.00 818.44
Total xenobiotics 444 1903.67 2064.51 10694.14
aIn addition to the non-ortho chlorinated PCBs (PCB #77, 126, and 169), only DDE, DDT, and the PCB congeners present in more than 75% of samples from Canadian women were
included in the mixture (20,21). Numbering system according to Ballschmiter and Zell (86). bMean concentration of non-ortho PCBs (19) and median concentration of other PCB and DDT
congeners (20,21). cDosing mixtures at the 10× and 100× level were prepared from dilution of the 1,000× mixture. The target concentrations are the expected quantities of organochlo-
rines dissolved in corn oil. dAnalyzed concentrations indicate the actual congener concentrations in the 1,000× dosing solution, measured in a blind test by Wellington Laboratories
(Guelph, Ontario, Canada). eAmounts given to the neonates when gavaged with 5.18 mL/kg of the 1,000× mixture at day 1 (a cumulative dose equal to 1,000 times human baby intake at
day 0, 1, 2, 3, 4), day 5 (a cumulative dose for day 5, 6, 7, 8, 9), day 10 (a cumulative dose for day 10, 11, 12, 13, 14), day 15 (a cumulative dose for day 15, 16, 17, 18, 19), and day 20 of age (a
cumulative dose for day 20, 21, 22, 23, 24). fPCB congeners are separated according to the position of the chlorine substitution. gThe analyzed concentration is 7.87 times higher than the
target concentration. This is the only major deviation from the target concentrations.chemicals included in the mixture were
> 99% pure (AccuStandard Inc., New
Haven, CT, USA), and were dissolved in
dimethylsulfoxide (DMSO), sometimes fol-
lowing heating at 55°C and sonication for 2
hr, before being diluted in corn oil at 50°C.
A blind analysis of the complete mixture was
performed to conﬁrm the concentrations of
each congener (Wellington Laboratories,
Guelph, Ontario, Canada). This analysis
revealed a very close match between our tar-
get and the analyzed concentrations, except
for PCB #77, which had a concentration
almost 8 times higher than expected. Some
of the discrepancies could be caused by
impurities in higher chlorinated PCBs (e.g.,
PCB #118). The composition and the doses
of the high dose mixture are indicated in
Table 1.
Animal treatment. Animal treatment
was conducted in accordance with the
Canadian Council on Animal Care guide-
lines (86). We could manipulate only a lim-
ited number of rats per week, so three litters
including only neonate female Sprague-
Dawley rats (10–11 females/litter) were pre-
pared every week by the supplier (Charles
River, St-Constant, Quebec, Canada), until
we accumulated over the weeks approxi-
mately 30 female neonates per treatment
group. On the day of arrival to the lab, at
neonatal day 1 (day 0 is the day of birth),
pups from all litters were separated from
their dams and regrouped under a heating
lamp. They were individually weighed, iden-
tified, and exposed by gavage to their first
treatment before being returned at random
to a fostering dam. Neonates were divided
into 7 separate treatment groups: corn oil
(0), 1,000×, MNU-0, MNU-10×, MNU-
100×, MNU-1,000×, and MNU-TCDD.
At ages 1, 5, 10, 15, and 20 days, the
neonates received the vehicle or appropriate
mixture by gavage, each dose representing 5
days of ingestion (Figure 1). At 18 days of
age, the MNU-TCDD group treated only
with oil at the above time points, also
received 2.5 µg TCDD/kg bw, dissolved in
corn oil by gavage [a dose 4 times smaller
than one previously shown to inhibit mam-
mary tumor development in the day 50
DMBA-induced rat model (66)]. On day 21
of age, all treatment groups, except the 0 and
the 1,000× group, received a single intraperi-
toneal (ip) injection of MNU (30 mg/kg bw,
dissolved in 0.9% NaCl, acidiﬁed to pH 4.0
with acetic acid), according to previous rec-
ommendations (87). The 0 and 1,000×
groups received the vehicle only. Rats were
weighed before each treatment and then
every 10 days. The time of vaginal opening
(assessed daily starting at day 25) was
recorded as an indicator of puberty. Twice a
week, beginning 4 weeks after the MNU
injection, rats were manipulated to detect
palpable tumors (the date, the location, and
size of the tumor were recorded). Seven and
nine rats from the 0 and 1,000× groups,
respectively, were sacriﬁced between 55 and
62 days of age, and the remaining rats from
these groups were sacrificed at 224 days of
age. MNU-treated rats were sacriﬁced when
their palpable tumors reached 1 cm, or by
308 days of age if no palpable tumor was
detected. Rats were sacriﬁced by exsanguina-
tion between 0900 and 1200 hr, under
isoﬂurane anesthesia. 
Analysis of the mammary gland struc-
tures. We recorded the locations and dimen-
sions of all palpable tumors from the time of
detection until necropsy. During necropsy,
the position and size of the tumors were
noted and the tumors were excised from the
mammary tissue, weighed, and cut in half,
with one-half ﬁxed in 10% neutral buffered
formalin (NBF) and the other half frozen in
liquid nitrogen. Paraffin sections (5 µm) of
the fixed mammary tumors were prepared
and stained with hematoxylin and eosin for
histologic classiﬁcation.
We prepared whole mounts by ﬁxing the
skin pelts in 10% NBF for 24–48 hr, and
then dissected all the mammary tissue. We
placed the left thoracic glands in tissue cas-
settes for later histologic analysis, and de-fat-
ted the rest of the mammary tissue in
acetone for 6 days and hydrated it with
100%, 95%, and 70% ethanol for 1 hr each
and with water for 30 min. We stained the
tissues by immersing them in Alum Carmine
Stain (0.4%) containing 0.015% thymol for
2 days. The glands were dehydrated (30 min
in water followed by 1 hr each in 70%,
95%, and 100% ethanol) and immersed in
xylene for a minimum of 1 hr. We then
sealed the stained mammary preparations in
plastic pouches containing methyl salicylate. 
We observed all abdominal-inguinal and
the right cervical-thoracic mammary glands
carefully under a stereoscope and then under
a microscope at 4× magniﬁcation. We noted
and identified the various mammary struc-
tures according to procedures described by
Russo and Russo (88). Structures that could
not be identified by analysis of the whole
mounts were dissected and transferred to
parafﬁn blocks before being classiﬁed by his-
tology (Table 2). In each animal we counted
individually the number of abnormal struc-
tures—including intraductal proliferations
(iDPs), microtumors, adenomas, hyperplas-
tic alveolar nodules, cysts, and other cystic
structures (buds, clumps, nodules, ducts,
lobules, milk-ﬁlled cysts). 
Statistical analysis. We performed all
analyses using JMP software (89). To ana-
lyze the time of vaginal opening and the
body weight (only when specific days were
considered), we tested homogeneity of vari-
ance by O’Brien and Brown-Forsythe tests,
and log-transformed the data when required
(body weight on day 40) before conducting
analysis of variance (ANOVA). Significant
ANOVA were followed by the Tukey-
Kramer all-comparison test to identify
groups with significantly different means.
We analyzed body weight changes through-
out the experiment by ANOVA on repeated
measures followed by contrast procedures to
determine differences between MNU- and
non-MNU–treated groups or to assess dif-
ferences between the MNU-1,000× group
and the other MNU groups. We used the
nonparametric median test to identify treat-
ment group differences in the number of rats
that developed more lesions than the median
of all groups (Table 2). We used chi-square
analyses to compare the percentage of rats
developing tumors among dose groups
(Table 3). We assessed differences in the
cancer incidence curves by survival curve
analysis, using the log-rank test, which places
more weight on later delay to tumor, and the
Wilcoxon test, which places more weight on
early delay to tumor. Signiﬁcant differences
were detected when p 0.05, whereas a p
0.1 suggested a tendency. 
Results
Treatment effects on body weight are shown
in Figure 2. There were no signiﬁcant effects
of the 1,000× dose compared to the 0 dose
on body weight throughout the study. The
TCDD treatment decreased growth rate,
even before the MNU injection, as indicated
by the smaller body weights of these rats on
days 20 and 21 (p = 0.0002) compared to
those of all other groups. These early effects
of TCDD on body weight did not persist, so
that by day 40 these rats were similar in weight
to the other MNU-treated rats. The MNU-
treated rats, regardless of the dose of the mix-
ture, had smaller body weights (ANOVA on
repeated measures, with contrast, p = 0.04)
than the 0 and the 1,000× groups through-
out the study, and this effect was signiﬁcant
as early as day 30 (p = 0.0001). Figure 2
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Figure 1. Exposure protocol. (A) Neonates at 1, 5, 10,
15, and 20 days of age were dosed by gavage with
the PCB/DDT/DDE mixture at 10, 100, and 1,000
times the amount that a human baby would con-
sume. (B) An additional group recived 2.5 µg
TCDD/kg bw by gavage at 18 days of age, instead of
the mixture. On day 21 of age, all treatment groups,
except for a control and a 1,000×-mix group,
received an ip injection of MNU (30 mg/kg bw).
PCB/DDT/DDE
051 0 15 20
MNU
MNU
TCDD
A
Bshows that the MNU-1,000× group had the
smallest body weights from approximately
day 75 until the end of the study, but these
were not signiﬁcantly different from those of
the other MNU-treated rats. 
The age at the time of vaginal opening
was similar in the 0, 1,000×, and the MNU-
1,000× dose groups (Figure 3). Except for
the MNU-1,000× group, vaginal opening
was delayed in all the MNU-treated rats, but
significantly (p = 0.02) only in the MNU-
10× and the MNU-100× groups.
Histologic analysis of all palpable tumors
and small mammary lesions dissected from
the whole mount preparations revealed the
existence of different types of benign and
malignant mammary lesions in the rat
(Table 2). The groups not treated with
MNU (0 and 1,000×) showed very few
mammary lesions compared to all the
groups treated with MNU. The most abun-
dant lesions were benign hyperplasia of
mammary cells within terminal end buds,
identiﬁed as iDPs, and hyperplasia of alveo-
lar and lobular structures. After all benign
and malignant lesions were pooled, the
number of rats that developed a number of
lesions above the median value signiﬁcantly
differed among MNU-treated groups (Table
2, p = 0.02), with more lesions developing in
the MNU-1,000× (median = 4.5; p = 0.05)
and MNU-TCDD (median = 5.5; p = 0.07)
than in the MNU-0 rats (median = 2).
Each point on the mammary tumor inci-
dence curves (Figure 4) represents the cumu-
lative percentage of rats that developed
palpable tumors (benign and malignant; not
including the microscopic lesions analyzed
from the whole mount preparations) over
time relative to the MNU injection (time =
0). Although the incidence curve of the
MNU-TCDD group tended to differ (p =
0.06) from that of the MNU-1,000× group,
none of the incidence curves differed signiﬁ-
cantly from that of the MNU-0 group.
However, if the data are censored at 150
days [approximately the last day in a similar
experiment (66)], the delay in the develop-
ment of tumors in the MNU-1,000× dose
group becomes statistically significant (p =
0.03). In addition, Figure 4 demonstrates
that at the end of the experiment the per-
centage of rats that developed palpable
mammary tumors was slightly increased (p =
0.06) by the MNU-TCDD (18/32 = 56%
rats with palpable tumors), but not by the
other treatments (MNU-1,000× 13/34,
38%; MNU-100× 11/31, 36%; MNU-10×
10/28, 36%) compared to controls (MNU-0
14/41, 34%).
The percentage of palpable tumors that
were malignant was higher (p = 0.02) in the
MNU-100× group (15/16, 94%) than in the
control group (10/18, 56%). In the MNU-
10×, MNU-1,000×, and MNU-TCDD
groups, these values were 70% (7/10), 73%
(11/15), and 72% (18/25), respectively.
These palpable tumors, whether malignant or
benign, were more often located in the
abdominal-inguinal region (66% of the
cases) than in the thoracic region (p = 0.002).
Table 3 reports the percentage of rats
with speciﬁc mammary lesions (palpable and
dissected from the whole mounts) per treat-
ment. There were no significant effects of
any of the organochlorine treatments on the
percentage of rats that developed lesions
among the MNU-treated groups. However,
the MNU treatment increased (p < 0.05) the
percentage of rats that developed mammary
lesions compared to the 0 or 1,000× groups.
The presence of cystic structures was com-
mon (~ 40%) among the 0 and the 1,000×
rats, and this incidence was further increased
(p = 0.03) by the MNU treatment.
The percentage of rats with nonmam-
mary tumors and/or organ abnormalities
was not altered by the 1,000× treatment,
but was significantly increased by the
MNU treatment (Table 4). Of particular
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Table 2. Total number, median, and range of mammary lesionsa per group.
MNU-treated mixture
0 1,000× 01 0 × 100× 1,000× TCDD
Mammary lesion (n = 30) (n  = 33) (n = 41) (n = 28) (n = 31) (n = 34) (n = 32) p-Valueb
Benign + malignant
n1 3 238 206 487 268 524
m0 02 21 4.5 5.5 0.02
r12 5 1 6 9 170 44 116
Benign
Fibroadenoma n 1 0 17 17 6 14 13
m0 00 00 00 0.24
r10 321 32
Papilloma n 0 0 7 3 14 1 50
m0 00 00 00 0.32
r00 43 1 1 12 0
Adenoma n 0 0 7 13 5 16 14
m0 00 00 00 0.68
r00 262 73
iDPc/hyperplasiad n0 2 118 144 335 156 331
m0 00 00 00 0.73
r02 2 8 6 4 140 37 61
Total n 1 2 149 177 360 187 408
m0 01 1.5 1 2 3.5 0.12
r12 3 4 6 4 140 37 82
Malignant
Carcinoma in situ n0 1 7 31 2 109 67 85
m0 00 00 00 0.55
r01 5 04 54 43 41
Adenocarcinoma n 0 0 16 17 18 14 31
m0 00 00 00 0.64
r00 444 21 2
Total n 0 1 89 29 127 81 116
m0 00 10 00 0.65
r01 5 15 54 43 53
Abbreviations: m, median (the median is preferred because it is not drastically affected by extreme values in non-normally distributed population as is the mean); n, number of lesions
per treatment group; r, range of lesions per treatment group (largest value – smallest value). 
aPalpable tumors plus those detected by a microscopic analysis of the whole mounts. bp-Value of the median test only among the MNU-treated rats. cPreneoplastic lesions that,
although benign, may grow to produce carcinomas. dHyperplasia of alveolar and lobular structures. importance was the induction of 12 renal
tumors that were not related to organochlo-
rine treatment.
Discussion
The results suggest that TCDD and the
highest dose of the PCB-DDT-DDE mix-
ture could modulate the development of
MNU-induced mammary tumors in the rat.
The MNU-TCDD and the MNU-1,000×
groups had similar effects in increasing the
median number of mammary lesions (Table
2), but the MNU-1,000× group, in contrast
to the MNU-TCDD group, transiently
delayed the development of palpable tumors.
Transient inhibition in the development
of palpable mammary tumors. The transient
inhibition in the development of palpable
mammary tumors observed in the MNU-
1,000× group but not in the MNU-TCDD
group (Figure 4) is a phenomenon similar to
that observed by Holcomb and Safe (66),
but is probably not solely attributable to the
activation of the Ah-R. After 10 µg/kg bw
TCDD was administered at day 50, a dose 4
times higher than ours, Holcomb and Safe
(66) observed at the end of their relatively
short experiment (140 days of age) that only
1/10 TCDD-treated rats, compared to 5/10
controls, developed DMBA-induced palpable
mammary tumor. Although they concluded
that TCDD prevented mammary tumor
development in the rat, perhaps they would
have observed only a transient delay if they
had performed a longer experiment. In our
experiment, the MNU-TCDD treatment
involved the administration of 87.5 ng
TCDD (or 2.5 µg/kg bw) at day 18, and
this did not inhibit tumor development.
Three times less TCDD-toxic equivalents
[TEQ (90, 91)] were administered to the
MNU-1,000× group (31.44 ng TCDD-TEQ
divided in ﬁve doses over the ﬁrst 20 days of
life) than with the MNU-TCDD treatment,
yet the MNU-1,000× group showed delayed
tumor development. [The TCDD-TEQ
value for the mixture was calculated using the
mean volume of the mixture administered to
the rats, the content of our mixture in Ah-R
agonists, and their toxic equivalency factors
(TEF) (PCB #77, 0.0001; #126, 0.1; #169,
0.01; #118, 0.0001; #156, 0.0005; #170,
0.0001, #180, 0.00005 (92)]. Therefore,
although the dosing regimes differ, mecha-
nisms other than those directly related to the
Ah-R binding might be involved.
The development of tumors induced by
MNU or DMBA treatments is predominantly
estrogen dependent (93–95). However, the
transient inhibition in the detection of pal-
pable tumors in the MNU-1,000× group
might not be linked to reduced ovarian
estrogen output or to anti-estrogenic effects.
Vaginal opening in the rat indicates puberty
and estrogen rise during the first estrous
cycle. The time to vaginal opening was not
delayed in the MNU-1,000× group; in fact,
it was accelerated compared to the MNU-
10× and MNU-100× groups (Figure 3).
Also, ovarian follicular development was not
altered by the 1,000× treatment in 21- and
224-day-old rats (96), suggesting that ovar-
ian estrogen output might not be altered.
Holcomb and Safe (66) suggested that the
antitumorigenic effects of TCDD are attrib-
utable to anti-estrogenic effects. TCDD and
AhR agonists (65,67) exert antiestrogenic
activity not by binding the estrogen receptor,
but indirectly by inducing phase I and phase
II drug-metabolizing enzymes [reviewed in
Schrenk (57)], by down-regulation of the
estrogen receptor (ER) and via crosstalk
between the AhR and ER signaling pathways
(58,97). However, antiestrogenic effects of
TCDD depend on dose, tissue, species, and
age, and are not detectable in 21-day-old rats
(98). At high dose the PCB-DDT-DDE
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Table 3. Number of rats with mammary lesionsa per group.
MNU-treated mixture
0 1,000× 01 0 × 100× 1,000× TCDD
Mammary lesion (n = 30) (n  = 33) (n = 41) (n = 28) (n = 31) (n = 34) (n = 32) p-Valueb
Benign + malignant
n 1228 24 22 25 24 0.54
% 3.3 6.1 68.3 85.7 71.0 73.5 75.0
Benign
Fibroadenoma n 1012 13 6 9 10 0.25
% 3.3 0 29.3 46.4 19.4 26.5 31.3
Papilloma n 00 31 31 5 0.33
%0 0 7.3 3.6 9.7 2.9 15.6
Adenoma n 00 54 48 6 0.70
%0 0 12.2 14.3 12.9 23.5 18.8
iDP/hyperplasia n 0116 9 10 14 15 0.73
%03.0 39.0 32.1 32.3 41.2 46.9
Total benign n 1126 18 17 24 22 0.72
% 3.3 3.0 63.4 64.3 54.8 70.6 68.8
Malignant
Carcinoma in situ n 01 55 87 4 0.55
%03.0 12.2 17.9 25.8 20.6 12.5
Adenocarcinoma n 0011 12 10 12 13 0.64
%0 0 26.8 42.9 32.3 35.3 40.6
Total malignant n 0115 15 12 15 14 0.70
%03.0 36.6 53.6 38.7 44.1 43.8
Other mammary observations
Cysts n 11 13 29 18 19 22 17 0.65
% 36.7 39.4 70.7 64.3 61.3 64.7 53.1
Fibrosis n 1024 21 18 19 18 0.51
% 3.3 0 58.5 75.0 58.1 55.9 56.3
Lactational changesc n 2021 17 17 18 11 0.30
% 6.7 0 51.2 60.7 54.8 52.9 34.4
Total n 11 13 32 23 25 28 25 0.98
% 36.7 39.4 78.1 82.1 80.7 82.4 78.1
Abbreviations: n, number of rats; %, percent of group. 
aPalpable tumors plus those detected by a microscopic analysis of the whole mounts. bThe p-value corresponds only to analysis of organochlorine effects within the MNU-treated rats;
given the large differences between MNU- and non-MNU–treated rats, the comparison of the seven groups was always highly signiﬁcant (p < 0.006), even for the incidence of cysts (p =
0.03), which is also elevated in the 0 and 1,000× groups. cObservation of milk secretions at necropsy or from the histologic analysis.mixture stimulated the proliferation of
MCF7-E3 cells in vitro, but had no
uterotrophic effects in vivo in immature
female rats (56). Thus, effects of the mixture
and TCDD on the development of the
mammary lesions may not be related only to
the estrogenic or antiestrogenic properties of
the chemicals.
Body weight differences among groups
of rats on the order of 15–20% are known to
inhibit mammary tumorigenesis (99). The
body weights of rats treated with MNU-
1,000× were less than 9% smaller than the
control group and were not signiﬁcantly dif-
ferent from the other MNU-treated rats
(Figure 2). We observed no inhibition of
tumor development in the MNU-TCDD
group even though the body weight was
18% smaller than that of the control group
on day 30 [this difference decreased with
aging (Figure 2)]. Thus, body weight differ-
ences cannot explain the transient inhibition
in the detection of palpable tumors. 
Increased number of mammary lesions.
In the absence of MNU, the mixture of
PCBs, DDT, and DDE does not induce the
development of abnormal mammary struc-
tures (Table 2 and 3). Similarly, over a
longer experiment, Kociba et al. (100)
observed no increase in mammary tumors in
the rat after dietary administration of 0.1 µg
TCDD/kg/day from 7 weeks of age up to 2
years. They even reported a decreased inci-
dence of spontaneous mammary tumors, but
at a toxic dose that decreased the fertility of
the rat (101) and induced hepatocarcinomas
(100). Thus, the mammary gland does not
appear to be a prime target for these chemi-
cals. However, the increased median number
of mammary lesions induced by MNU-
TCDD and MNU-1,000× (Table 2) and
the increased percentage of rats that devel-
oped palpable mammary tumors in the
MNU-TCDD group (Figure 4) suggest that
these treatments favored the initiation
and/or promotion phases of the carcinogenic
process. Others found that the carcinogenic
potential of chemical initiators (DMBA or
MNU) is increased by the administration of
TCDD in utero (68), or at relatively low
doses of PCB #77 (64), compared to high
[PCB #77 (65); TCDD (66)] or repetitive
doses (67) of Ah-R agonists, which reduced
tumor development. Brown et al. (68) sug-
gested that TCDD treatment in utero poten-
tiates the carcinogenic effects of DMBA by
increasing the number of terminal end buds
(TEBs) at the time of the DMBA injection
at 50 days of age; the TEBs are suggested to
be the target sites for the carcinogenic effects
of chemical initiators (102). We observed no
effects of the mixture on the size of the mam-
mary glands or the number of TEBs at 21
days of age, the time of MNU injection (96).
In vitro, a malignant transformation bioassay
demonstrated that without pretreatment
with initiating agents, no malignant foci are
observed after continuous TCDD/PCB
treatments; but extremely low concentra-
tions of TCDD or PCB #126 (10–13 M),
after initiation, promote malignant transfor-
mation (103). Collectively these results and
ours suggest the existence of multiple time-
and dose-dependent mechanisms modulat-
ing the development of chemically induced
mammary tumors.
Tumor location and phenotype. In our
study, most of the palpable tumors were
from the abdominal-inguinal glands. In
other studies in which tumors were initiated
with DMBA (68) or MNU (86,104) at day
50 of age, tumors were located mostly in the
thoracic region. Asynchronous postnatal
development of the cervical-thoracic versus
abdominal-inguinal glands was suggested to
explain the predominance of thoracic tumors
(88). We are not aware of other articles
reporting the location of mammary tumors
induced with MNU at 21 days of age in
long-term studies. Perhaps at this age, the
number of target cells for MNU is larger in
the abdominal-inguinal chains of mammary
glands than in the thoracic-cervical ones.
The percentage of malignant tumors
was significantly higher in the 100× treat-
ment group than in the control group, sug-
gesting that the phenotype of the tumors
might be modiﬁed by the mixture treatment.
Nesaretnam et al. (64) observed that DMBA-
induced tumors from rats treated with PCB
#77 were mostly of the invasive phenotype.
This observation is further supported by the
fact that extremely low concentrations of
TCDD or PCB #126 (10–13 M) promoted
malignant transformation (103). In our
study, changes in tumor phenotype did not
follow a dose relationship, so this observation
must be conﬁrmed by other studies.
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Figure 2. Effects of treatment on body weight. The 0 and 1,000× groups had
similar body weights throughout the experiment. All groups treated with MNU
had significantly lower body weights than the 0 or 1,000× groups. The inset
highlights a significant reduction in body weight starting at day 20 (*) in the
MNU-TCDD group, before MNU injection, and at day 30 in all groups treated
with MNU. 
Figure 3. Effects of treatment on the age at vaginal opening occurrence. A sig-
niﬁcant ANOVA was obtained, and the Tukey-Kramer all-comparison test iden-
tified groups with significantly different means (p < 0.05). Bars with different
letters are significantly different. The number above each bar represents the
number of rats per treatment group.
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abRelevance to human disease. Given the
absence of detectable effects at the lowest
dose level, our study might suggest that in
humans the neonatal level of exposure to the
chemicals included in our mix does not
modulate tumor development. Regardless of
the changes in tumor phenotype in the
MNU-100× dose group, the increase in the
median number of lesions occured at a dose
representing 1,000 times the amount of
PCBs (19 congeners), DDT, and DDE that
a human baby would consume during the
ﬁrst 24 days of life. In fact, the safety margin
could be larger than 1,000. The concentra-
tions of organochlorines in milk samples are
not normally distributed, and the mixture
contained non-ortho chlorinated PCBs
based on mean levels, not the median levels;
consequently, the proportions of non-ortho-
chlorinated PCBs in the mixture exceed the
proportions expected in most human milk
samples. In addition, the amount of these
PCBs in the mixture was slightly increased
by the presence of eight times more PCB
#77 than what we expected (Table 1). This
difference might not have biologic conse-
quences given that the TCDD-TEF for
PCB #77 is 0.0001 (92), and it modiﬁes the
total TCDD-TEF exposure dose for the
complete mixture from 31.42 to 31.44 ng.
Nevertheless, a lack of information on the
effects of more complete mixtures and on the
effects occuring in utero, and a lack of under-
standing of the relations between toxicologic
and carcinogenic processes, prevent us from
ruling out the possibility of a link between
TCDD, PCB, DDT, and DDE exposure and
the risk of developing some types of breast
cancer. Twenty-seven percent of the risk of
developing breast cancer in twins derives from
heritable factors (5). Twins are likely to
receive similar exposures during the perinatal
period, so the risk associated with in utero
and/or neonatal exposure to organochlorines
is likely to be smaller than 27%. Finally, the
body burden in the human population is
declining (69), which should decrease the risk
for the general population even further.
The modulation of chemically induced
mammary tumor development by organo-
chlorines is an expensive but important
experimental model for studying the initia-
tion and the promotional phases of carcino-
genesis. Moreover, it is one of the rare animal
models providing quantiﬁable late outcomes
following in utero or neonatal exposure to
low doses of contaminants. Given that in the
absence of an initiator, organochlorines have
no effects on mammary tumor development,
more research is required using the MNU or
DMBA model to understand their mecha-
nisms of action and how they are modulated
by environmental contaminants. Such stud-
ies should determine the usefulness of this
model as an indicator of adverse effects in
humans, and could be used to identify epi-
demiologic markers of breast cancer suscep-
tibility, and thus improve epidemiologic
investigations.
In summary, we have shown that expo-
sure during the neonatal period to TCDD
or a mixture of PCBs, DDT, and DDE,
before MNU treatment at neonatal day 21
increased the median number of mammary
lesions (palpable and microscopic, benign
and malignant) developing in the adult rat.
The percentage of rats that developed palpa-
ble tumors (benign plus malignant) was also
higher in the MNU-TCDD group than in
the control group. The highest dose of the
mixture delayed the development of palpable
tumors, but the MNU-TCDD treatment
did not. Perhaps treatments with TCDD or
the highest dose of the mixture sensitize the
mammary tissue to the carcinogenic effects
of MNU by altering the initiation/early pro-
motion phase of the carcinogenic processes.
Then, the MNU-1,000× group exerted a
transient inhibition of promotional mecha-
nisms up to approximately 150 days after
the MNU injection, or selected tumorigenic
tissues responsive only to the late promo-
tional factors. We are now assessing the
dose–response effects of neonatal exposure to
Ah-R agonists in human milk on the devel-
opment of mammary lesions. It will remain
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Figure 4. Mammary tumor incidence curves. Each
point represents the cumulative percentage of
rats that developed palpable tumors (benign and
malignant) relative to the time of MNU injection
(time = 0). The incidence curve of the MNU-TCDD
group differs almost significantly (p = 0.06) from
the MNU-1,000× group. None of the incidence
curves significantly differed from the MNU-0
group. At the end of the experiment the percent-
age of rats that developed palpable mammary
tumors was slightly increased (p = 0.06) by the
MNU-TCDD (18/32 = 56% rats with palpable
tumors) but not by the other treatments (MNU-
1,000× 13/34, 38%; MNU-100× 11/31, 36%; MNU-
10× 10/28, 36%) compared to controls (MNU-0
14/41, 34%).
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Table 4. Incidence (percent of animals) of nonmammary tumors and organ abnormalities from tissues dissected during necropsy.
MNU-treated mixture
Nonmammary tumors/ 0 1,000× 01 0 × 100× 1,000× TCDD
abnormalities (n = 30) (n = 33) (n = 41) (n = 28) (n = 31) (n = 34) (n = 32)
Fibroma 0 0 2.4 0 0 0 0
Ameloblastomaa 00 2.4 0 0 0 0
Keratoacanthomab 00 2.4 3.6 0 0 3.1
Fibrohistiocytic tumor 0 0 0 0 0 0 3.1
Epidermoid cyst 0 0 2.4 0 0 8.8c 0
Abscessed salivary gland 0 0 0 0 0 0 3.1
Kidneyd 3.3 0 7.3 10.7 3.2 2.9 6.3
Ovarye 00 14.6 17.9 6.5 17.6 12.5
Uterus 3.3f 0 4.9g 3.6h 0 2.9i 0
Adrenalj 00 2.4 7.1k 3.2 2.9 0
Pituitary glandl 00 4.9 0 3.2 2.9 3.1
Spleen 0 3.0m 00 0 0 3.1n
Fur loss 0 0 0 3.6 3.2 0 3.1
aTooth-related. bSkin tumors. cOne animal had three epidermoid cysts. dAll abnormal kidneys (12 in total) were renal mesenchymal tumors, except for one (MNU-0) which was glomeru-
lonephritis. In one animal (MNU-10×) both kidneys were abnormal. eAll ovarian follicular cysts (abnormally large clear follicles), except one thecoma (MNU-TCDD), one hemorrhagic
ovarian cyst (MNU-10×), and one atrophic ovary (MNU-10×). fNot histologically classified, uterine bleeding. gOne enlarged uterus (not classified), one with an endometrial polyp.
hEndometritis. iFocal cystic hyperplasia. jAdrenals were abnormally enlarged, but not histologically classiﬁed except for one (MNU-1,000×) which was a hemorrhagic infarction (not
specific to treatment). kOne enlarged adrenal was next to a kidney with a renal mesenchymal tumor. lAbnormal pituitary glands were not histologically classified. A dark area was
observed on three pituitaries (MNU-0, MNU-100×, and MNU-TCDD groups), a white spot on an MNU-0–treated, and an MNU-1,000×–treated pituitary gland had blood inside. mEnlarged,
not classiﬁed. nTwo small cysts on side of spleen, not classiﬁed.to be determined whether differences in the
development of mammary lesions between
treatment groups resulted from immediate
toxic effects at the time of MNU injection,
from persistent toxic effects, or from long-
term effects altering the physiology of aging.
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